Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Beating the odds: a cardiomyocyte cell line at last
Jeffrey M. Leiden
Jeffrey M. Leiden
Published March 1, 1999
Citation Information: J Clin Invest. 1999;103(5):591-592. https://doi.org/10.1172/JCI6471.
View: Text | PDF
Commentary

Beating the odds: a cardiomyocyte cell line at last

  • Text
  • PDF
Abstract

Authors

Jeffrey M. Leiden

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Derivation and potential applications of bone marrow stroma–derived card...
Derivation and potential applications of bone marrow stroma–derived cardiomyocyte cell lines. Schematic illustration of the derivation of the CMG bone marrow stroma–derived cardiomyocyte cell line. Solid arrows indicate the work reported by Ogawa and colleagues (4) in this issue of the JCI. Dotted lines show potential applications of the cardiomyocyte cell line in studies designed to identify cardiomyocyte-determining genes (1), or in cell replacement therapies for patients with cardiomyopathy (2, 3).
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts